Sfoglia per Autore
The role of histamine in doxorubicin and teniposide-induced cardiotoxicity in dog and mouse
1987-01-01 Gebbia N.; Flandina C.; Leto G.; Tumminello F.M.; Sanguedolce R.; Candiloro V.; Gagliano M.; Rausa L.
Does P-glycoprotein-170 expression predict for chemoresistance in transitional cell carcinoma of the bladder?
2002-01-01 Sanguedolce, R.; Calascibetta, A.; Porcasi, R.; Melloni, D.; Pavone, C.; Maria Tomasino, R.; Pavone-Macaluso, M.
Correlation between GP-170 expression, prognosis, and chemoresistance of superficial bladder carcinoma
2003-01-01 Serretta, V; Pavone, C; Allegro, R; Vella, M; Sanguedolce, R; Porcasi, R; Morello, V; Tomasino, RM; Pavone, M
Clinical relevance of thymidylate syntetase expression in the signet ring cell histotype component of colorectal carcinoma
2004-01-01 CABIBI, D; CALASCIBETTA, A; CAMPIONE, M; BARRESI, E; RAUSA, L; DARDANONI, G; ARAGONA, F; SANGUEDOLCE, R
Thymidylate Synthase polymorphism and microsatellite instability: association in colorectal cancer
2004-01-01 CALASCIBETTA A; RAUSA L; GULLOTI L; BUETTNER R; SANGUEDOLCE R
LOW CELL PROLIFERATION AND LOW THYMIDYLATE SYNTHASE LEVELS IN THE HIGHLY AGGRESSIVE SIGNET RING CELL VARIANT HISTOTYPE OF COLORECTAL CARCINOMA
2004-01-01 SANGUEDOLCE R; M CAJOZZO; L RAUSA; F ARAGONA; G SANGUEDOLCE; G DI FEDE; A CALASCIBETTA
Low cell proliferation marker and low thymidylate synthase levels in the highly aggressive signet ring cell variant histotype of colorectal carcinoma
2004-01-01 SANGUEDOLCE R; CABIBI D; CAJOZZO M; RAUSA L; ARAGONA F; SANGUEDOLCE G; DI FEDE G; CALASCIBETTA A
Low cell proliferation marker and low thymidylate synthase levels in the highly aggressive signet ring cell variant histotype of colorectal carcinoma
2004-01-01 SANGUEDOLCE R; CABIBI D; CAJOZZO M; RAUSA L; ARAGONA F; SANGUEDOLCE G; DI FEDE G; CALASCIBETTA A
The significance of the Thymidylate Synthase expression in the Signet Ring Cell component of colorectal carcinoma
2004-01-01 CALASCIBETTA A; CAMPIONE M; BARRESI E; RAUSA L; DARDANONI G; ARAGONA F; SANGUEDOLCE R
Thymidylate synthase gene promoter polymorphisms are associated with TSmRNA expressions but not with microsatellite instability in colorectal cancer
2004-01-01 CALASCIBETTA A; CABIBI D; MARTORANA A; SANGUEDOLCE G; RAUSA L; FEO S; DARDANONI G; SANGUEDOLCE R
Associations between polymorphisms in the thymidylate synthase gene, the expression of thymidylate synthase mRNA and the microsatellite instability phenotype of colorectal cancer
2004-01-01 MERKELBACH BRUSE, S; HANS, V; MATHIAK, M; SANGUEDOLCE, R; ALESSANDRO, R; RUSCHOFF J; BUTTNER, R; HOUSHDARAN, F; GULLOTTI, L
DIFFERENCE IN KI67 AND THYMIDYLATE SYNTHASE, P53 LEVELS AND THE TREATMENT BY CMF DRUG COMBINATION VERSUS TAXANES IN THE LOCALLY ADVANCED CARCINOMA OF THE BREAST
2005-01-01 SANGUEDOLCE R; RAUSAL; CABIBI D; ARAGONA F; BARRESI E; MARTORANA A CALASCIBETTA A
Relationship between the thymidiylate synthase, P53 levels and the treatment by CMF drug combination versus taxanes in the locally advanced carcinoma of the breast
2005-01-01 SANGUEDOLCE R; RAUSA L; CABIBI D; ARAGONA F; BARRESI E; MARTORANA A; CALASCIBETTA A
RELATIONSHIP BETWEEN THE THYMIDYLATE SYNTHASE, p53 LEVELS AND THE TREATMENT BY CMF DRUG COMBINATION VERSUS TAXANES IN THE LOCALLY ADVANCED CARCINAMO OF THE BREAST
2005-01-01 SANGUEDOLCE R; RAUSA L; CABIBI D BARRESI E; MARTORANA A; CALASCIBETTA A
Relationship between the thymidylate synthase, p53 levels and the treatment by CMF drug combination versus taxanes in the locally advanced carcinoma of breast.
2005-01-01 SANGUEDOLCE R; RAUSA L; CABIBI D; ARAGONA F; BARRESI E; MARTORANA A; CALASCIBETTA A
Difference in ki67 and thymidylate synthase expression in primary tumour compared with metastastic nodes in breast cancer patients. european society for the study of purine and pyrimidine metabolism in man
2005-01-01 CALASCIBETTA A; RAUSA L; CABIBI D; ARAGONA F; BARRESI E; MARTORANA A; SANGUEDOLCE R
Difference in Ki67 and Thymidylate synthase expression in primary tumour compared with metastatic nodes in breast cancer patients
2005-01-01 RAUSA L; CALASCIBETTA A; CABIBI D; ARAGONA F; BARRESI E; MARTORANA A; SANGUEDOLCE R
Relationdhip between the thymidylate synthase, P53 levels and the treatment by CMF drug combination versus taxanes in the locally advanced carcinoma of breast
2005-01-01 SANGUEDOLCE R; RAUSA L; CABIBI D; ARAGONA F; BARRESI E; MARTORANA A; CALASCIBETTA A
Difference in ki67 and thymidylate synthase expression in primary tumour compared with metastastic nodes in breast cancer patients
2005-01-01 CALASCIBETTA A; CABIBI D; RAUSA L; ARAGONA F; BARRESE E; MARTORANA A; SANGUEDOLCE R
RELATIONSHIP BETWEEN THYMIDYLATE SYNTHASE EXPRESSION AND p53 LEVELS WITH THE TREATMENT BY CYCLOPHOSPHAMIDE, 5-FLUOROURACIL CHEMOTHERAPY (CMF) VERSUS DOCETAXEL IN THE LOCALLY ADVANCED CARCINOMA OF THE BREAST.
2006-01-01 M BRANDI; A CALASCIBETTA; D CABIBI; A MARTORANA; F ARAGONA; F FULFARO; M VALERIO; J DISPENZA; SANGUEDOLCE R
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile